Clinical trials to date have demonstrated that treatment with Galvus results in sustained reductions in blood sugar levels, leading to improved glucose control. The most common side effects seen in the Galvus clinical program were cold/flu-like symptoms, headaches and dizziness.
“There is a great need to get people to their target blood sugar. To do this, we need effective treatments that don't increase the risk for hypoglycaemia or low blood sugar,” said Richard Pratley, professor of medicine, diabetes & metabolism translational medicine unit at the University of Vermont.
Galiant is a three-month multi-center trial that plans to enroll more than 7,500 patients. The study will be conducted in a “real world” setting involving predominantly primary care physicians.
The trial is designed to demonstrate that once-daily Galvus is as effective as a TZD in improving blood sugar control in a primary care setting.